TABLE OF CONTENTS

WELCOME MESSAGE ......................................................................................... 5
IASLC & CONFERENCE COMMITTEE ................................................................. 7
International Association for the Study of Lung Cancer ............................... 8
Conference Committee ................................................................................... 8
GENERAL CONFERENCE INFORMATION ..................................................... 11
Health & Safety Measures at NACLC 2022 ...................................................... 11
Floor Plan ........................................................................................................ 11
Conference Registration ................................................................................. 12
Poster Viewing & Networking Breaks .............................................................. 12
Breakfast .......................................................................................................... 12
Onsite Service & General Information ............................................................ 12
Press & Media .................................................................................................. 14
CONTINUING MEDICAL EDUCATION (CME) INFORMATION ......................... 17
INFORMATION FOR SPEAKERS & ABSTRACT PRESENTERS ......................... 21
NACLC 2022 EDUCATION AWARDS ............................................................... 23
SCIENTIFIC PROGRAM ................................................................................... 27
Program at a Glance ........................................................................................ 27
Friday, September 23, 2022 ........................................................................... 28
Saturday, September 24, 2022 ...................................................................... 29
Sunday, September 25, 2022 ......................................................................... 32
POSTER SESSIONS ........................................................................................ 35
POSTER DISCUSSIONS .................................................................................... 41
ABSTRACT AUTHOR INDEX ........................................................................... 43
EXHIBIT & INDUSTRY SUPPORTER INFORMATION ....................................... 49
Exhibition Hours .............................................................................................. 49
Exhibition Events & Highlights ...................................................................... 49
Industry Supporter & Exhibitor List ................................................................. 50
Exhibit Floor Plan ............................................................................................ 51
Exhibitor Descriptions .................................................................................... 52
INDUSTRY SYMPOSIA .................................................................................... 57
Welcome Message

Dear Colleagues, Friends, Sponsors and Exhibitors,

On behalf of the International Association for the Study of Lung Cancer (IASLC) we are pleased to welcome you to the IASLC 2022 North America Conference on Lung Cancer (#NACLC22) at the Chicago Marriott Downtown Magnificent Mile. The North America Conference on Lung Cancer is a dynamic meeting with a long tradition and close to 500 participants will join us this year to discuss important topics related to thoracic malignancies. The Conference is a fabulous opportunity to network across disciplines with other people with careers focused on thoracic malignancies and learn about the latest developments in prevention, detection and care with novel data presentations. We encourage you to actively participate in the discussions, engage with our industry supporters and join us for the poster viewing reception on Saturday evening. We are also hosting a special Networking Lunch Women’s Forum on Sunday, September 25 which all delegates are welcome to attend.

We also would like to extend our gratitude and thanks to all industry supporters and exhibitors for their support to NACLC and the IASLC. Without them this Conference would not be possible.

Thank you for joining us in Chicago.

We look forward to hosting all of you over the next couple of days.

Best Regards,

Jessica Donington, MD  
NACLC 2022 Co-Chair

Everett Vokes, MD  
NACLC 2022 Steering Committee

Marina Garassino, MD  
NACLC 2022 Co-Chair

Heather Wakelee, MD  
NACLC 2022 Steering Committee

Jyoti Patel, MD  
NACLC 2022 Co-Chair

Everett Vokes, MD  
NACLC 2022 Steering Committee

Heather Wakelee, MD  
NACLC 2022 Steering Committee
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 6,000 lung cancer specialists from over 100 countries.

IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. The IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

The IASLC mission is:

- To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies.
- To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public.
- To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.

## IASLC Staff

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karen Kelly</td>
<td>Chief Executive Officer</td>
</tr>
<tr>
<td>John Skadow</td>
<td>Chief Financial Officer</td>
</tr>
<tr>
<td>Matt Yeingst</td>
<td>Chief Development Officer</td>
</tr>
<tr>
<td>Tessa Baxter</td>
<td>IASLC Foundation Coordinator / Project Manager</td>
</tr>
<tr>
<td>Becky Bunn</td>
<td>Senior Advisor, Scientific Relations</td>
</tr>
<tr>
<td>Mya Burns</td>
<td>Associate Director, Conferences</td>
</tr>
<tr>
<td>Casey Connolly</td>
<td>Scientific Affairs Specialist</td>
</tr>
<tr>
<td>Bailey Creamer</td>
<td>Editorial Assistant</td>
</tr>
<tr>
<td>Kathy Doherty</td>
<td>Director, Human Resources</td>
</tr>
<tr>
<td>Ken Harrell</td>
<td>Database Administrator</td>
</tr>
<tr>
<td>Kelly Heemsbergen</td>
<td>Conference Manager</td>
</tr>
<tr>
<td>Kelsey Heckler</td>
<td>Conference Coordinator</td>
</tr>
<tr>
<td>O’Ryan Jackson</td>
<td>Administrative Assistant</td>
</tr>
<tr>
<td>Van Sin Lim</td>
<td>Editorial Consultant JTO Clinical and Research Reports</td>
</tr>
<tr>
<td>Sara Lindsay Patton</td>
<td>Patient Advocacy Specialist</td>
</tr>
<tr>
<td>Katie Maher</td>
<td>Member Experience Specialist</td>
</tr>
<tr>
<td>Sunhee Malinowski</td>
<td>Account Manager</td>
</tr>
<tr>
<td>Jan Mazotti</td>
<td>Associate Director, Marketing and Communications</td>
</tr>
<tr>
<td>Karen Muth</td>
<td>Executive Assistant and Board Liaison</td>
</tr>
<tr>
<td>Rodrigo Sagastegui</td>
<td>Marketing Specialist</td>
</tr>
<tr>
<td>Mary Todd</td>
<td>Managing Editor, JTO &amp; JTO CRR</td>
</tr>
<tr>
<td>Kelsey Wood</td>
<td>Associate Director, Member Experience</td>
</tr>
<tr>
<td>Kelly Wright</td>
<td>Member Experience Coordinator</td>
</tr>
<tr>
<td>Murry Wynes</td>
<td>Senior Advisor, Scientific Affairs</td>
</tr>
<tr>
<td>Kexin Yu</td>
<td>Accountant</td>
</tr>
<tr>
<td>Flavia Zarcula</td>
<td>Corporate Relations Manager</td>
</tr>
</tbody>
</table>

999 17th Street, Suite 200
Denver, Colorado 80202-2725
Phone: 1-855-GO-IASLC (1-855-464-2752)
IASLC Board of Directors 2021 – 2023

**Officers**
- **President**: Heather Wakelee, United States
- **Past-President**: Tetsuya Mitsudomi, Japan
- **President-Elect**: Paul Van Schil, Belgium
- **Secretary**: Andrea Bezjak, Canada
- **Treasurer**: Erik Thunnissen, Netherlands
- **Chief Executive Officer**: Karen Kelly, United States

**Board of Directors**
- **Joachim Aerts**, Netherlands
- **Carlos Gil Moreira Ferreira**, Brazil
- **Jhanelle Gray**, United States
- **Roy Herbst**, United States
- **Young Tae Kim**, South Korea
- **Morten Quist**, Denmark
- **Lecia Sequist**, United States
- **Ming-Sound Tsao**, Canada
- **Paula Ugalde**, United States
- **Caicun Zhou**, China

**Meeting Co-Chairs**
- **Jessica Donington**, United States
- **Marina Garrasino**, United States
- **Jyoti Patel**, United States

**Steering Committee**
- **Everett Vokes**, United States
- **Heather Wakelee**, United States

**Program Committee**

**Medical Oncology**
- **Frank Weinberg**, United States
- **Greg Durn**, United States
- **Angel Qin**, United States
- **Mary Jo Fidler**, United States
- **Salama Waar**, United States
- **Christine Bestvina**, United States

**Radiation Oncology**
- **Aditya Juloori**, United States
- **Pamela Sampson**, United States
- **Gaurav Marwaha**, United States

**Pathology**
- **Aliya Husain**, United States
- **Mary Beth Beasley**, United States

**Surgery**
- **David Odell**, United States
- **Duy Khanh Cepka**, United States
- **Erich Gillaspie**, United States

**Pulmonology**
- **Tim Murgu**, United States
- **Scott Ferguson**, United States

**Translational Science**
- **Mohamed Abazeed**, United States
- **Sean Prieto**, United States
- **Jessica Lin**, United States
- **Tina Ciacone**, United States

**Mesothelioma, Thymoma**
- **Hedy Lee Kindler**, United States
- **Anne Tsao**, United States
- **Patrick Loehrer**, United States

**Tobacco Control, Environmental Exposure, Risk Reduction and Screening**
- **Jim Mulshine**, United States
- **Loretta Erhunmwenusee**, United States
- **Betty Tran**, United States

**Community Practice**
- **Jane Liu**, United States
- **Avanti Ragam**, United States

**Nursing & AHP**
- **Liva Saeto**, United States
- **Michelle Tumer**, United States

**Patient Advocacy**
- **Upal Basu Roy**, United States
- **Jill Feldman**, United States
- **Ivy Elkins**, United States

Immunohistochemistry is an extremely valuable and powerful technique for pathologic diagnosis.

Published by the IASLC and its Pathology Committee, the IHC Atlas takes a comprehensive look at diagnostic IHC and its role in thoracic pathology.

The IHC Atlas is a useful reference for anyone interested in thoracic tumor diagnostics, from basic researchers to practicing oncologists. All pathologists should have access to these best practices. The Atlas is available in multiple languages.

Scan the QR code to order your copy today!

**Coming Soon!**
IASLC Atlas on Molecular Biomarker Testing for Targeted Therapy
Available at #TTLC23

International Association for the Study of Lung Cancer

Conquering Thoracic Cancer

International Association for the Study of Lung Cancer

Interact International Association for the Study of Lung Cancer

Published by the IASLC and its Pathology Committee, the IHC Atlas takes a comprehensive look at diagnostic IHC and its role in thoracic pathology.

The IHC Atlas is a useful reference for anyone interested in thoracic tumor diagnostics, from basic researchers to practicing oncologists. All pathologists should have access to these best practices. The Atlas is available in multiple languages.

Scan the QR code to order your copy today!
The IASLC 2022 North America Conference on Lung Cancer (NACLC 2022) is being held at the Chicago Marriott Downtown Magnificent Mile. Session rooms, Exhibit and Poster Hall, and Registration are located on the 5th Floor, except for the Opening Keynote Session and CURE® Lung Cancer Heroes® Cocktail Reception, on September 23, 2022 which will be held at Marriott Ballroom and Halstead Foyer on the 4th Floor.

NACLC 2022 will be hosted as an in-person meeting in Chicago, Illinois, USA at the Chicago Marriott Downtown Magnificent Mile. The health and safety of all our stakeholders are of the utmost importance. Although we are excited to welcome you to Chicago, all necessary precautions will be taken to ensure a safe environment throughout the Conference.

The following measures are in place and enforced on-site to achieve this commitment (applicable to all staff, delegates, exhibitors, industry supporters, and guests):

VACCINATION POLICY
NACLC 2022 recommends that all in-person attendees are fully vaccinated against COVID-19 by the time of the Conference. Fully vaccinated refers to completing the approved first 2 vaccines, as per the guidelines of their country of residence.

All participants, including attendees, speakers, staff, and suppliers will be asked to present proof of full vaccination and photo ID with a matching name prior to entry into the Conference Venue.

Accepted Forms of Proof:
(Note: Proof of vaccination must match the Attendee’s name)
- Copy of an official certificate from your Country/State/Province
- Photo of the official certificate
- Digital PDF or document of the official certificate on a mobile device
- Accepted Vaccines: as per approved guidelines from the country of residence

In the absence of a proof of vaccination, the IASLC will accept a valid negative test result (from within 24 hours to 48 hours), with no symptoms.

If you cannot or choose not to comply with the IASLC health and safety protocols, or if you are unable to come to Chicago, please join us virtually for #NACLC22.

MASK REQUIREMENT
Masks will be encouraged to be worn at NACLC 2022.

By registering to attend, you agree that:
You will not attend if you have any COVID-19 symptoms
If during your attendance you develop any COVID-19 symptoms, you will immediately:
- Self-isolate;
- Comply with all local/national government restrictions;
- and
- Inform the NACLC 2022 Conference Secretariat by email (naclc2022-Registration@icsevents.com).

IASLC and their suppliers will in their best effort, provide a safe environment to meet. It is expected that all participants will follow the measures to help reduce the risk.

Please note: There is no on-site testing facility available at NACLC 2022.
**Conference Registration**

- **Registration Counter | 4th Floor**
  - Friday, September 23
  - 12:00 PM - 3:00 PM

- **Registration Counter | 5th Floor**
  - Saturday, September 24 and Sunday, September 25
  - 8:00 AM - 5:00 PM

- **Registration Desk Hours**
  - Friday, September 23: 4th Floor, 15:30 - 19:30
  - Saturday, September 24: 5th Floor, 06:00 - 19:30
  - Sunday, September 25: 5th Floor, 06:00 - 13:00

**Poster Viewing & Networking Breaks**

- **(Snacks and refreshments provided)**
  - Saturday, September 24: Chicago Ballroom FGH | 5th Floor
    - 09:30 - 10:00
    - 14:30 - 15:00
  - Saturday, September 24 (Poster Viewing Reception)
    - 17:40 - 18:55
  - Sunday, September 25: 09:15 - 09:45

**Networking Breakfast & Lunch**

- A light breakfast/lunch will be provided.
  - Saturday, September 24: Chicago Ballroom Foyer | 5th Floor
    - 07:00 - 08:00
  - Sunday, September 25: 07:00 - 08:00

**Name Badges**

- Attendees are requested to wear their name badges at all times in order to participate in the Scientific Sessions and Exhibitions.

**Networkin Breaks Supporter**

- **Pfizer Oncology**
- **EMD Serono**

**Poster Viewing Reception Supporter**

- **EMD Serono**
- **Serono**

**Saturday Networking Breakfast Supporter**

- **Pfizer Oncology**

**Saturday Networking Luncheon Supporter**

- **Pfizer Oncology**

**Sunday Networking Breakfast Supporter**

- **EMD Serono**

**Women in Lung Cancer Networking Luncheon Supporter**

- **Regeneron**

**Prayer / Mothers Room**

- IASLC is offering delegates the use of a private nursing room and the use of a multifaith prayer room located at the Kansas City Room on the fifth floor.

**Prayer / Mothers Room Timings**

- **Saturday, September 24**
  - 06:00 - 20:30
- **Sunday, September 25**
  - 06:00 - 13:30

**Lost and Found / Messages**

- Lost and found items should be returned / claimed at the Registration Desk.

**Networking Breaks**

- On the Conference days, refreshments will be available outside the Exhibit and Poster Hall during the scheduled morning and afternoon Networking Breaks.

**PARKING**

- The Hotel has off-site Parking located at the corner of Rush & Ohio Street. Please contact Chicago Marriott Downtown Magnificent Mile for further details.

**Posters Online**

- All abstracts accepted for poster presentations will be presented as traditional printed posters to be displayed on poster boards in the Exhibit and Poster Hall (Chicago Ballroom FGH). In addition to the printed poster, each presenter is required to submit an electronic version of their poster to be made available in the virtual meeting platform, which is available to all registered delegates.

**Smoking**

- The Chicago Marriott Downtown Magnificent Mile is a smoke-free environment. All public areas, rental space, corridors, loading docks, Exhibit and Poster Halls, and parking lots are designated non-smoking. The Chicago Marriott Downtown Magnificent Mile is required to enforce the no-smoking rules.

**Attendees are required to wear their name badges at all times within the venue.**

**Breakfast**

- A light breakfast will be provided in the Chicago Ballroom Foyer on the 5th Floor from 07:00 - 08:00 on Saturday, September 24 and Sunday, September 25.

**Poster Viewing Reception Supporter**

- **Women in Lung Cancer Networking Luncheon Supporter**

**Poster Viewing Reception Supporter**

- **Regeneron®**

**Lost and Found / Messages**

- Lost and found items should be returned / claimed at the Registration Desk.

**Networking Breaks**

- On the Conference days, refreshments will be available outside the Exhibit and Poster Hall during the scheduled morning and afternoon Networking Breaks.

**PARKING**

- The Hotel has off-site Parking located at the corner of Rush & Ohio Street. Please contact Chicago Marriott Downtown Magnificent Mile for further details.

**Posters Online**

- All abstracts accepted for poster presentations will be presented as traditional printed posters to be displayed on poster boards in the Exhibit and Poster Hall (Chicago Ballroom FGH). In addition to the printed poster, each presenter is required to submit an electronic version of their poster to be made available in the virtual meeting platform, which is available to all registered delegates.

**Smoking**

- The Chicago Marriott Downtown Magnificent Mile is a smoke-free environment. All public areas, rental space, corridors, loading docks, Exhibit and Poster Halls, and parking lots are designated non-smoking. The Chicago Marriott Downtown Magnificent Mile is required to enforce the no-smoking rules.

**Attendees are required to wear their name badges at all times within the venue.**

**Breakfast**

- A light breakfast will be provided in the Chicago Ballroom Foyer on the 5th Floor from 07:00 - 08:00 on Saturday, September 24 and Sunday, September 25.

**Poster Viewing Reception Supporter**

- **Women in Lung Cancer Networking Luncheon Supporter**

**Poster Viewing Reception Supporter**

- **Regeneron®**

**Lost and Found / Messages**

- Lost and found items should be returned / claimed at the Registration Desk.

**Networking Breaks**

- On the Conference days, refreshments will be available outside the Exhibit and Poster Hall during the scheduled morning and afternoon Networking Breaks.

**PARKING**

- The Hotel has off-site Parking located at the corner of Rush & Ohio Street. Please contact Chicago Marriott Downtown Magnificent Mile for further details.

**Posters Online**

- All abstracts accepted for poster presentations will be presented as traditional printed posters to be displayed on poster boards in the Exhibit and Poster Hall (Chicago Ballroom FGH). In addition to the printed poster, each presenter is required to submit an electronic version of their poster to be made available in the virtual meeting platform, which is available to all registered delegates.

**Smoking**

- The Chicago Marriott Downtown Magnificent Mile is a smoke-free environment. All public areas, rental space, corridors, loading docks, Exhibit and Poster Halls, and parking lots are designated non-smoking. The Chicago Marriott Downtown Magnificent Mile is required to enforce the no-smoking rules.

**Attendees are required to wear their name badges at all times within the venue.**

**Breakfast**

- A light breakfast will be provided in the Chicago Ballroom Foyer on the 5th Floor from 07:00 - 08:00 on Saturday, September 24 and Sunday, September 25.

**Poster Viewing Reception Supporter**

- **Women in Lung Cancer Networking Luncheon Supporter**

**Poster Viewing Reception Supporter**

- **Regeneron®**

**Lost and Found / Messages**

- Lost and found items should be returned / claimed at the Registration Desk.

**Networking Breaks**

- On the Conference days, refreshments will be available outside the Exhibit and Poster Hall during the scheduled morning and afternoon Networking Breaks.

**PARKING**

- The Hotel has off-site Parking located at the corner of Rush & Ohio Street. Please contact Chicago Marriott Downtown Magnificent Mile for further details.

**Posters Online**

- All abstracts accepted for poster presentations will be presented as traditional printed posters to be displayed on poster boards in the Exhibit and Poster Hall (Chicago Ballroom FGH). In addition to the printed poster, each presenter is required to submit an electronic version of their poster to be made available in the virtual meeting platform, which is available to all registered delegates.

**Smoking**

- The Chicago Marriott Downtown Magnificent Mile is a smoke-free environment. All public areas, rental space, corridors, loading docks, Exhibit and Poster Halls, and parking lots are designated non-smoking. The Chicago Marriott Downtown Magnificent Mile is required to enforce the no-smoking rules.

**Attendees are required to wear their name badges at all times within the venue.**

**Breakfast**

- A light breakfast will be provided in the Chicago Ballroom Foyer on the 5th Floor from 07:00 - 08:00 on Saturday, September 24 and Sunday, September 25.
DISCLAIMER
The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.

PRESS & MEDIA
Pre-registered Press and Media representatives are required to check-in at the registration desk. Non-registered Press and Media representatives should also proceed to the registration desk and need to provide their press/media credentials to receive their Conference name badge.

USE OF NACLC 2022 SCIENTIFIC PROGRAM CONTENT
Please be aware that the information and materials displayed and/or presented at all sessions of this meeting are the property of the International Association for the Study of Lung Cancer (IASLC) 2022 North America Conference on Lung Cancer and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced or distributed without the written permission of the IASLC. Use of the NACLC/IASLC name and/or logo in any fashion by any commercial entity for any purpose is expressly prohibited without the written permission of the IASLC.

Editor-in-Chief:
Alex A. Adjei, MD, PhD, FACP
Chairman, Taussig Cancer Institute – Cleveland Clinic, Cleveland, OH USA

The Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies. JTO emphasizes a multidisciplinary approach, and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. The audience consists of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.

Learn more at JTO.org
A subscription to JTO is a benefit of membership in the IASLC. To join, visit www.IASLC.org.
CONTINUING MEDICAL EDUCATION (CME) INFORMATION

PURPOSE
The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity and scientific rigor for all Continuing Medical Education (CME) activities.

DISCLOSURE OF FINANCIAL RELATIONSHIPS
In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships and those are mitigated according to ACCME Standards for Integrity and Independence in Accredited Continuing Education before the individual can assume their role in the activity.

For the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022), disclosure information will be available for viewing as of September 22, 2022. Presenters are also required to include a disclosure slide listing all relevant financial relationships with ineligible companies. CME related questions should be directed to IASLC at cme@iaslc.org.

DISCLOSURE OF COMMERCIAL SUPPORT
The International Association for the Study of Lung Cancer received support for this activity from the Accreditation Council for Continuing Medical Education (ACME) to provide continuing medical education for physicians.

ACME ACCREDITATION AND AMA DESIGNATION STATEMENT
The International Association for the Study of Lung Cancer (IASLC) is accredited by the Accreditation Council for Continuing Medical Education (ACME) to provide continuing medical education for physicians.

The IASLC designates this “Other Activity” (a live conference offered in hybrid format including recorded and virtual participation) for a maximum of 16 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

TARGET AUDIENCE
The IASLC 2022 North America Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, physician assistants and nurses. The Conference is also designed to provide a forum for lung cancer patients and patient advocates to receive education and share their perspectives with the lung cancer community.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. Apply evidence-based recommendations and clinical practice guidelines to diagnose and treat patients with lung cancer and other thoracic malignancies.
2. Describe the impact of COVID-19 on lung cancer care, research, and prevention efforts.
3. Describe scientific advances in lung cancer and other thoracic malignancies.
4. Synthesize research from clinical trials and translational studies to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
5. Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, and implementing early screening.
6. Engage and empower patients to become active participants in their treatment.

OFFICIAL LANGUAGE
The official language of the IASLC 2022 North America Conference on Lung Cancer is English.

DISCLAIMER
The information presented at the IASLC 2022 North America Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
HOW TO RECEIVE A CME CERTIFICATE (PHYSICIANS ONLY)
Physicians are entitled to receive a CME certificate after completing the Conference evaluation survey. A link to this survey will be emailed to all attendees at the conclusion of the Conference; the survey can also be accessed from the Conference website. After submitting the survey, physicians have the option to print or save their CME certificate.

The deadline for claiming CME credits is December 31, 2022. Please direct any certificate inquiries to: cme@iaslc.org

HOW TO RECEIVE A CERTIFICATE OF ATTENDANCE (NON-PHYSICIANS)
Non-physicians are entitled to receive a “Certificate of Attendance.” To claim a Certificate of Attendance, non-physicians must first complete the Conference evaluation survey. A survey link will be emailed to all attendees at the conclusion of the Conference; the survey can also be accessed from the Conference website. After submitting the survey, attendees may print or save their Certificate of Attendance.

The deadline for receiving a Certificate of Attendance is December 31, 2022. Please direct any certificate inquiries to: cme@iaslc.org

Submit Your Abstract
Showcase your research and contribute to discussions that will shape the future of treatments in lung cancer and thoracic malignancies.

#LALCA23
www.lalca2023.iaslc.org/call-for-abstracts/
DISCLOSURE INFORMATION
All speakers must include a slide with their financial disclosure information. Without a disclosure slide you will not be allowed to present.

PRESENTATION SLIDE TEMPLATE
All speakers are encouraged to use the IASLC/NACLC presentation slide template for their presentation.

INVITED SPEAKERS AND ORAL PRESENTERS
All speakers are asked to be in the session room at least 15 minutes prior to the start of their session.

Please provide your presentation slides to the Speaker Preview Center, in Denver Room on the 5th Floor at least 2 hours prior to your presentation, or as of the opening hours on Saturday, September 24. The use of personal laptops for presentations is not allowed as it can cause technical delays and cut into a presenter’s time.

No file submissions will be accepted in the session rooms.

Poster Presenters
All Poster Presentation Boards are located in the Exhibit and Poster Hall

Poster Display Time
*Poster Print-out order with NACLC 2022 Secretariat only.

Poster Presenters
Saturday, September 24
07:00 – 16:30
Sunday, September 25
07:00 – 12:00

Presenters in Attendance
Saturday, September 24
09:30 – 18:55
Sunday, September 25
09:15 – 12:30

Poster Pick Up*
Saturday, September 24
06:00 – 08:00

*Poster Print-out order with NACLC 2022 Secretariat only.

Poster Set Up Times
Saturday, September 24
06:00 – 08:00

Poster Take Down Time
Sunday, September 25
12:30 – 13:30
Congratulations to the NACLC 2022 Education Award Winners!

Award Winners will be presented with their awards during the Opening Session on Friday, September 23 from 17:30 – 18:30 in the Marriott Ballroom on the 4th Floor.

Eunji Choi  
Stanford University School of Medicine, United States  
OA01.01: Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked  
Oral Abstract Session 01 (OA01)  
Saturday, September 24 | 15:00 – 16:40  
Chicago Ballroom ABCD

Nathaniel Deboever  
The University of Texas MD Anderson Cancer Center. Department of Thoracic and Cardiovascular Surgery, United States  
PP01.06: Circulomic Variables May Predict Pathologic Staging Preoperatively in Treatment-Naïve Non-Small Cell Lung Cancer  
Poster Viewing Reception  
Saturday, September 24 | 17:40 – 18:55  
Exhibit and Poster Hall

Lei Deng  
Roswell Park Comprehensive Cancer Center, United States  
PP01.71: Survival Outcome of Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: A Study of National Cancer Database  
Poster Viewing Reception  
Saturday, September 24 | 17:40 – 18:55  
Exhibit and Poster Hall

Donna Phan  
Montefiore Medical Center, United States  
PP01.04: Hispanic Patients are at Higher Risk for Delayed Time to Surgery Following Identification of a Solid Lung Nodule  
Poster Viewing Reception  
Saturday, September 24 | 17:40 – 18:55  
Exhibit and Poster Hall

Julie Wu  
Stanford University, United States  
PP01.05: Impact of PD-L1 Status on Survival on Immunotherapy Monotherapy in Real-World Patients with Poor Performance Status: A US Nationwide Veterans Affairs Study  
Poster Viewing Reception  
Saturday, September 24 | 17:40 – 18:55  
Exhibit and Poster Hall
## Program at a Glance

### Scientific Sessions

<table>
<thead>
<tr>
<th>CT</th>
<th>Friday September 23, 2022</th>
<th>Saturday September 24, 2022</th>
<th>Sunday September 25, 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30</td>
<td>Networking Breakfast</td>
<td>Networking Breakfast</td>
<td></td>
</tr>
<tr>
<td>7:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>Keynote Session 01 (KANC)</td>
<td>Opening</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>Keynote: Lung Cancer Care Delivery</td>
<td>in Multidisciplinary Setting</td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>Welcome Reception: CURC Long Cancer Research Awards Ceremony</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Registration Hours:
- Friday, September 23: 06:00 - 18:30
- Saturday, September 24: 07:00 - 12:00
- Sunday, September 25: 07:00 - 13:00

Speaker Preview Center Hours:
- Saturday, September 24: 07:00 - 16:30
- Sunday, September 25: 07:00 - 12:00

Exhibit Hours:
- Saturday, September 24: 08:30 - 18:00
- Sunday, September 25: 08:15 - 12:15

Conquering Thoracic Cancers Worldwide
Impacted.

together the lung cancer community to end the stigma of the disease, inform, connect, and empower anyone who has been

the individual lives of those living with the disease. Along with our sponsor and various advocacy groups, CURE® is bringing

by patients, caregivers, advocates or health care professionals for their heroic contributions in the field of lung cancer or in

CURE® is proud to host the 2022 Lung Cancer Heroes® recognition ceremony, an evening of gratitude and celebration for the

19:30 – 21:00 | Marriott Ballroom | 4th Floor

Light refreshments and beverages will be provided.

Cure® Lung Cancer Heroes® Awards Ceremony

19:30 – 21:00 | Marriott Ballroom | 4th Floor

CURE® is proud to host the 2022 Lung Cancer Heroes® recognition ceremony, an evening of gratitude and celebration for the
heroes who have made a significant impact in the lives of patients with lung cancer. Each Lung Cancer Hero is nominated
by patients, caregivers, advocates or health care professionals for their heroic contributions in the field of lung cancer or in
the individual lives of those living with the disease. Along with our sponsor and various advocacy groups, CURE® is bringing
together the lung cancer community to end the stigma of the disease, inform, connect, and empower anyone who has been

Impact.
Keynote Session 02 (KN02) – Cancer Immunotherapy: Targeting Immune Dysfunctions in Tumor Sites
13:30 – 14:30  Chicago Ballroom ABCD | 5th Floor
Chair(s) Jessica Donington, United States & Heather Wakelee, United States
13:30 – 13:35  Welcome
Jessica Donington, United States & Heather Wakelee, United States
13:35 – 14:15  KN02.01: Cancer Immunotherapy: Targeting Immune Dysfunctions in Tumor Sites
Liping Chen, United States & Jyoti Patel, United States
14:15 – 14:30  Q&A Discussion

Poster Discussion (PPD01)
16:40 – 17:40  Chicago Ballroom ABCD | 5th Floor
Chair(s) DayaRanah Cappa, United States & Hedy Lee, United States
16:40 – 17:40  PPD01.03 Discussant
Melanie Smith, United States
PPD01.03: Patterns of Use of Medical Cannabis in Lung Cancer and Other Cancer Patients
Deepthi Behl, United States

17:10 – 17:20  Poster Viewing Reception
Chicago Ballroom FGH | 5th Floor

16:55 - 17:10  PPD02.04: Discussant
Mohamed Abazeed, United States
PPD02.04: Three-year Outcomes per Month Analysis of the In-Hospital Needs of Lung Cancer Survivors with Advanced Non-Small Cell Lung Cancer
Marta Pela, United States

17:20 – 17:40  PPD04.04: Discussant
Jonathan Ries, United States
PPD04.04: Survival Associations of T Cell Clusters with Immunotherapy in Mesothelioma
Aakash Desai, United States

17:40 – 18:55  Poster Viewing Reception
Chicago Ballroom FGH | 5th Floor

REFRESHMENTS PROVIDED
Sunday, September 25, 2022

07:00 – 08:00 Networking Breakfast
Chicago Ballroom Foyer | 5th Floor

Education Session 04 (ES04): Implications for Immunotherapy in Subsets of Patients with Thoracic Disease

08:15 – 09:15 Chair(s)
Chicago Ballroom ABCD | 5th Floor
Young Kwang Chae, United States & Heather Wakelee, United States

Welcome
Young Kwang Chae, United States & Heather Wakelee, United States

08:17 - 08:27 ES04.01: New Era for Mesothelioma Aaron Mansfield, United States

08:27 - 08:37 ES04.02: 2022 Primer on Thymoma and Thymic Carcinoma Nisha Movva, United States

08:37 - 08:47 ES04.03: Immunotherapy in Older Patients with Lung Cancer Carolyn Presley, United States

08:47 - 08:57 ES04.04: Risk Factors for Immune Related Adverse Events: Implication for Identification and Early Intervention Balazs Halmos, United States

08:57 - 09:07 ES04.05: Considerations for Duration and De-escalation of Immunotherapy Ryan Gentzler, United States

09:07 - 09:15 Q&A Discussion

Education Session 05 (ES05): SCLC and Important Updates in Thoracic Oncology - Updates from WCLL

08:15 – 09:15 Chair(s)
Chicago Ballroom E | 5th Floor
Greg Durm, United States & Jill Feldman, United States

Welcome
Greg Durm, United States & Jill Feldman, United States

08:17 - 08:27 ES05.01: First Line Treatment for Extensive Stage SCLC Siddhartha Devakonda, United States

08:27 - 08:37 ES05.02: New Agents for Second and Further Lines Saiama Waqar, United States

08:37 - 08:47 ES05.03: The Evolving Role of Radiotherapy in SCLC Aditya Juloori, United States

08:47 - 08:57 ES05.04: Case Study for Limited Stage Shrut Patel, United States

08:57 - 09:15 Q&A Discussion

Education Session 06 (ES06): Medical Oncology - Translational Science and Immunotherapy

09:45 - 11:15 Chair(s)
Chicago Ballroom E | 5th Floor
Mohamed Abazeed, United States & Lecia Sequist, United States

Welcome
Mohamed Abazeed, United States & Lecia Sequist, United States

09:45 - 09:47 ES06.01: Optimal Frontline Therapy for Immunotherapy Marina Chiara Garassino, United States

09:47 - 10:02 ES06.02: New Strategies to Overcome Immune Checkpoint Resistance John Wrangle, United States

10:02 - 10:17 ES06.03: LKB1 and KEAP1, Prognostic or Predictive Factors? Lecia Sequist, United States

10:17 - 10:32 ES06.04: Role of Liquid Biopsy for Early Diagnosis Lecia Sequist, United States

10:32 - 10:47 ES06.05: Role of Liquid Biopsy in Monitoring Progression Christian Rolfo, United States

10:47 - 11:02 ES06.06: The Evolving Role of Immunotherapy in Subsets of Patients with Thoracic Disease Heather Wakelee, United States

11:02 - 11:15 Q&A Discussion

Keynote Session 03 (KN03): Closing Keynote – The Rapid Evolution of Peri-operative Immune Therapy in NSCLC

11:15 – 12:15 Chair(s)
Jessica Donington, United States

Welcome
Jessica Donington, United States

11:15 – 11:20 Jessica Donington, United States

11:20 – 12:00 KN03.01: The Rapid Evolution of Peri-operative Immune Therapy in NSCLC Heather Wakelee, United States

12:00 – 12:15 Q&A Discussion

Women’s Forum Networking Lunch (WF01)

12:30 – 13:30 Chair(s)
WF01.01: Women’s Forum Networking Lunch Panel Karen Kelly, United States, Heather Wakelee, United States, Jessica Donington, United States, Marina Chiara Garassino, United States & Jyoti Patel, United States
Poster Sessions

Exhibit and Poster Hall | Chicago Ballroom FGH | 5th Floor

PP01.01 People (NCT03447678), a Phase II Trial to Test Biomarkers of Response to Pembrolizumab as First-Line Treatment in Advanced NSCLC Patients with PD-L1<50%.
Marina Chiara Garassino, United States

PP01.02 Molecular Recurrence Risk Profiles in Patients with Early-Stage NSCLC: Current Standard of Care Compared to a Prognostic and Predictive 14-gene Expression Assay
Julie Hufham, United States

PP01.03 Flagging High-Risk Individuals with a ML Model Improves NSCLC Early Detection in a USPSTF-Eligible Population
Eran Netanel Choman, Israel

PP01.04 Hispanic Patients are at Higher Risk for Delayed Time to Surgery Following Identification of a Solid Lung Nodule
Donna Phan, United States

PP01.05 Impact of PD-L1 Status on Survival on Immunotherapy Monotherapy in Real-World Patients with Poor Performance Status: A US Nationwide Veterans Affairs Study
Julie Wu, United States

PP01.06 Circulomic Variables may Predict Pathologic Staging Preoperatively in Treatment-Naive Non-Small Cell Lung Cancer
Nathaniel Deboever, United States

PP01.07 Identifying Patient Barriers to Adherence in Lung Cancer Screening
April Plank, United States

PP01.08 Circulating Genetically Abnormal Cells Predicts Risk of Lung Cancer in Individuals with Indeterminant Pulmonary Nodules
Benjamin A. Katchman, United States

PP01.09 Genotypic Characteristics and Resistance Mutations in Advanced ALK+ NSCLC: The ALK-PATHFINDER Study
Santiago Ponce Aix, Spain

PP01.10 A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory (R/R) NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Jonathan Rhode, United States

PP01.11 Furmonertinib is an Oral, Irreversible, Highly Brain-Penetrant Pan-EGFR Inhibitor with Activity Against Classical and Atypical EGFR Mutations
Luna Musib, United States

PP01.12 Increasing Diagnosis of Ground Glass Nodules and Semi-Solid Lung Lesions on Chest CT Scans over the Past Decade
Gavitt Woodard, United States

PP01.13 Low Screening Rates in Patients Ultimately Diagnosed with Advanced NSCLC
Joseph Fuchs, United States

PP01.14 The Utilization of Molecular Risk Stratification of Early-Stage Non-Small Cell Lung Cancer to Identify Increase Failure Despite Complete Surgical Resection
K-Adam Lee, United States

PP01.15 Circulating Tumor DNA (ctDNA) Level: a Prognostic Biomarker for Clinical Outcomes in Non-Small Cell Lung Cancer (NSCLC) Patients Across Diverse Therapy Classes
Layla Mowlavi, United States

PP01.16 Improving Access to Early Palliative Care Delivery for Patients with an Advanced Thoracic Malignancy Through an Embedded Onco-Palliative Clinic Model
Carolyn Presley, United States
NACLC 2022 | Conference Program Book

PP01.17 Sotorasib in Advanced KRAS p.G12C–Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)
Jessica Bauman, United States

PP01.18 Surgical Resection after Targeted Therapy in Stage IV NSCLC: Nuances and Considerations
Mara Antonoff, United States

PP01.19 Volatile Organic Compound Biomarkers Identification for Prediction of Lung Cancer Based on Exhaled Breath Analysis
Yoo Hwa Hong, Republic of Korea

PP01.20 Trial in Progress: Screening for High Frequency Malignant Disease (SHIELD)
Lindsey Cotton, United States

PP01.21 Utilization of Pre- and Post-Stereotactic Body Radiotherapy (SBRT) Neutrophil-to-Lymphocyte (NLR) Ratios and Platelet-to-Lymphocyte (PLR) Ratios as Prognostic Factors in Early-Stage Non-Small Cell Lung Cancer
Neha Sharma, United States

PP01.22 First Lung Cancer Screening Program in Greece - Initial Experience, Preliminary Data and Pitfalls.
Nikolaos Kofou, Greece

PP01.23 Outcomes of Stage IIIA Disease in NSCLC, Treated with Surgery - A Single Institution Experience
Prashanth G Sarm, India

PP01.24 5-Year Survival Outcomes of Lung Cancer Treated with Surgery: A Single Institution Experience
Prashanth G Sarm, India

PP01.25 Incidence and Timing of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor as Monotherapy or in Combination With Chemotherapy
Austin Secor, United States

PP01.26 Evaluation of Automated Sample Preparation System for Lymph Node Sampling
Jennifer Duke, United States

PP01.27 Real-World Effectiveness of Second-Line Therapies for Metastatic Non-Small Cell Lung Cancer
Lyudmila Bazhenova, United States

PP01.28 Tumor Engraftment is Prognostic for Disease Recurrence in Resected Non-Small Cell Lung Cancer
Bindiya G. Patel, United States

PP01.29 Prevalence and Predictor of Significant Unmet Needs in Patients who were Surgically Resected for Non-Small Cell Lung Cancer
Melissa L. Johnson, United States

PP01.30 Are Delays In The Diagnosis Of Lung Cancer Due To Patients First Seeking Treatment for Tuberculosis in Rural India?
Sasmita Menakuru, United States

PP01.31 Real-World Treatment Outcomes of Amivantamab in Pre-A approval Access (PA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)
Joshua Sabari, United States

PP01.32 Proteasome Hyperactivity as a Targetable Vulnerability in Oncogenic Missense TP53 Mutated NSCLC
Ezifa Oduah, United States

PP01.33 Serum Autoantibodies may help Identify Individuals with Actionable Pulmonary Nodules on LDCT Scan.
Claire Auger, United States

PP01.34 Induction of Tertiary Lymphoid Structures in Non-Small Cell Lung Cancer Improves B and T Cell Anti-Tumor Immunity
Hye Mi Kim, United States

PP01.35 Validation of a High-Specificity Blood-Based Autoantibody Test to Detect Lung Cancer in Pulmonary Nodules
Trevor Pitcher, United States

#NACLC22 | naclic2022.iaslc.org

PP01.36 Blood-Based Biomarker Testing in Advanced Non-Small Cell Lung Cancer: Adoption, Biomarker Assessment, and Therapy Selection
Katherine T. Lodgren, United States

PP01.37 Quality of Life in Non-Small Cell Lung Cancer Patients With Brain/CNS Metastases: Real-World Evidence
Stan Krulewicz, United States

PP01.38 Biomarker Testing and Associated Treatment patterns in Advanced Non-Small Cell Lung Cancer in the US
Stan Krulewicz, United States

PP01.39 Infrastructure for Interobserver Variability Assessment of Pathologic Response (PR), in Surgical Resection Specimens Following Neoadjuvant Immune Check Point Inhibitor (ICI) Therapies in Early Stage NSCLC
Neus Bota-Rabasses, United States

PP01.40 Target Lesion Response and Outcomes in Patients Treated with Brigatinib vs Crizotinib in ALTA-1L
Pingkuan Zhang, United States

PP01.41 Efficacy of Sotorasib Versus Standard Chemotherapy + Immunotherapy in KRAS G12C Mutated Lung Cancer: A Comparative Study Modeling Real-World Data
Philip Haddad, United States

PP01.42 Efficacy of Adagrasib Versus Standard Chemotherapy +/- Immunotherapy in KRAS G12C Mutated Lung Cancer: A Comparative Study Modeling Real-World Data
Philip Haddad, United States

PP01.43 A Retrospective Single-Center Analysis of Patients with Atypical EGFRm NSCLC Treated with First-Line EGFR-TKIs
Xuening Li, United States

PP01.44 Long-Term Survival and Outcomes by Race from the Phase I/II trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced NSCLC: HCRN LUN1-175
Ryan Gnetzler, United States

PP01.45 Implementation Challenges and Disparities in Molecular Testing for Patients with NSCLC at a Safety-Network Hospital
Laura Burns, United States

PP01.46 Unfiltered Patient Insights: Experiences of Patients With ALK+ or EGFR Exon20 Insertion+ Non-Small Cell Lung Cancer
Kim Gibbs, United States

PP01.47 HERTHENA-Lung02: A Randomized Phase 3 Study of Patritumab Deruxtecan vs Platinum-Based Chemotherapy in Locally Advanced or Metastatic EGFR-Mutated NSCLC After Progression with a Third Generation EGFR TKI
Balazs Halmos, United States

PP01.48 Efficacy and Safety of Patritumab Deruxtecan (HER3-Dx) in Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) without EGFR-Activating Mutations
Melissa L. Johnson, United States

PP01.49 Analysis of Outcomes by Race in Patients with Advanced NSCLC
Danielle Dressler, United States

PP01.50 EMERGE-201: Phase 2 Basket Study of Lurbinectedin Monotherapy in Advanced or Metastatic Solid Tumors
Debasis Chakrabarti, United States

PP01.51 Cost-Efficiency and Budget-Neutral Expanded Access Modeling of Topirolimab over Pembrolizumab in Advanced NSCLC
Karen MacDonald, United States

PP01.52 Budget Impact Analysis of Topirolimab Versus Pembrolizumab in Previously Untreated Advanced Squamous NSCLC
Karen MacDonald, United States

PP01.53 Pathologic Response Assessment Tool – Architecting a Cloud-Based Tool to Streamline Logistics for Shipping, Tracking, Scoring, and Reporting.
Juan Pasadas Ruiz, United States
PP01.54  ImmunoBlood: A Prospective Study Evaluating the Development of Anti-Checkpoint Inhibitor Antibodies in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
Corrado Oriuolo, Italy

PP01.55  Real-World Treatment Sequencing and Impact on Outcomes in ALK-Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC)
Yin Wan, United States

PP01.56  Peripheral T-Cell Receptor Repertoire Dynamics in Patients with Small Cell Lung Cancer
Mendith L Balbach, United States

PP01.57  Evaluation of the Metabolism of the Biogenic Amines on the Neuroendocrine Differentiation of A549 Adenocarcinoma Cells
Irasmia Mendietla, Mexico

PP01.58  Multi City Opportunistic Screening of Lung Nodules amidst COVID-19
Ankit Modi, India

PP01.59  Performance of a Deep Learning Algorithm for the Early Detection of Malignant Lung Nodules
Anish Chhaparwal, India

PP01.60  Double the Lung Cancer Early Detection Rates with Incidental Lung Nodule Program
William Mayfeld, United States

PP01.61  First-Line Treatment Patterns of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) with and without BRAF Mutations in the US
Maria Cecilia Vieira, United States

PP01.62  Therapeutic Potential of Folate Conjugated Actinonin Encapsulated Human Serum Albumin Nanoformulation Against Lung Adenocarcinoma Model.
Priyanca Ahlawat, India

PP01.63  Real-World Assessment of Clinical Outcomes Associated with Immunotherapy (IO) and chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients with Brain Metastases and METexon14 Skipping Mutations Treated in US Community Centers
Sieleli Cai, United States

PP01.64  A Safety and Efficacy Analysis Comparing Elderly vs Nonelderly Patients Treated with Consolidation Immunotherapy after Chemoradiation for stage III NSCLC from the BTCRC LUN 16-081 Clinical Trial
Shabha Shahani, United States

PP01.65  Treatment Patterns of Malignant Pleural Mesothelioma in a Resource Limited Setting: A “Real World” Study
Karina Morales Hernandez, Mexico

PP01.66  A Case of Metastatic HER2-Amplified Non-Small-Cell Lung Cancer (NSCLC) Treated with Trastuzumab Deruxtecan
Karen Jun, United States

PP01.67  Decentralized, Real-World Study of Aflatinib in Patients with Advanced/Metastatic Solid Tumors with NRGI Fusions
Stephen Liu, United States

PP01.68  Registry Based Analysis of Radiation Modality on Survival with Definitive Chemoradiation for Stage III Non Small Cell Lung Cancer (NSCLC)
Andrew Grass, United States

PP01.69  NSCLC with Testicular Metastasis: A Case Report
Anna-Lena Meinhardt, United States

PP01.70  Prevalence, Treatment Patterns, and Survival by Age in Patients Diagnosed with Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Brain Metastases (BM) in the USA
Melissa Laurie, United States

PP01.71  Survival Outcome of Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: A Study of National Cancer Database
Lei Deng, United States

PP01.72  Cell-free DNA for Treatment Response and Recurrence Monitoring in Advanced Stage Lung Cancer
Stephen Yu, United States

PP01.73  Time from Biopsy to Treatment Initiation at an Academic Hospital and Affiliate Hospitals: Overall Survival Analysis
Chetan Vakkalagadda, United States

PP01.74  Clinical Validation of a Promising New Amplicon-Based Liquid Biopsy Platform for Detection of Guideline Recommended Biomarkers in Metastatic NSCLC
Richa Dawar, United States

PP01.75  Neuro-Cognitive Effects of WBRT and HS-PCI in LS-SCLC
Suranjkanta Acharya, India

PP01.76  Lurbinectin vs an External Control Arm in Patients with Small Cell Lung Cancer
Xue Wang, United States

PP01.77  EMERGE 402: Real-world Characteristics and Safety of Lurbinectin in Small-cell Lung Cancer (SCLC)
Firas Badin, United States

PP01.78  Brain Metastasis in Patients with KRAS Mutant Advanced NSCLC Receiving Docetaxel: Pooled Clinical Trial Data Analysis
Sukhmann Padda, United States

PP01.79  ALK Positive, Inc - Patient Advocacy Accelerating Research and Clinical Trials Worldwide
Scott Schell, United States

PP01.80  Long Term Results of VATS Lobectomy for Early Staged Non Small Cell Lung Cancer
Do Kim Que, Viet Nam
**Poster Discussions**

- **PPD01.01** Patterns of Use of Medical Cannabis in Lung Cancer and Other Cancer Patients  
  Deepti Behl, United States

- **PPD01.02** Identifying Physical, Social, Emotional, and Medical Needs of Lung Cancer Survivors with Advanced Non-Small Cell Lung Cancer  
  Mattea Miller, United States

- **PPD02.01** Comprehensive Genomic Profiling (CGP) for Diagnostic Clarity in Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC)  
  Umit Tapan, United States

- **PPD02.02** Tepotinib + Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT  
  Richard OHara, United States

- **PPD02.03** Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Analysis of All Patients From VISION Cohorts A and C  
  Marina Chiara Garassino, United States

- **PPD03.01** Adjuvant Radiation Therapy in Clinical Stage III (N2) Non-Small Cell Lung Cancer after Neoadjuvant Chemotherapy  
  Takefumi Komiya, United States

- **PPD04.01** Survival Associations of T Cell Clusters with Immunotherapy in Mesothelioma  
  Aakash Desai, United States

- **PPD04.02** First-Line Nivolumab + Ipilimumab (NIVO+IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227  
  Hossein Borghaei, United States

- **PPD04.03** Risk of Further Progression or Death among Non-small Cell Lung Cancer Patients with Durable Disease Control Enrolled in Immunotherapy Trials  
  Lei Deng, United States

*Poster Discussions*  
Chicago Ballroom AB/CD | 5th Floor | 16:40 - 17:40
<table>
<thead>
<tr>
<th>Abstract Author Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abraham, Ivo PP01.51, PP01.52</td>
</tr>
<tr>
<td>Achariya, Suryakant PP01.16</td>
</tr>
<tr>
<td>Agahi, Ali Reza PP01.01</td>
</tr>
<tr>
<td>Agne, Julia PP01.16</td>
</tr>
<tr>
<td>Agnelli, Luca PP01.01</td>
</tr>
<tr>
<td>Ahlawat, Priyanka PP01.16</td>
</tr>
<tr>
<td>Ahmad, Ali Reza PP01.01</td>
</tr>
<tr>
<td>Ahn, Myung-Ju PP01.40, PP01.76</td>
</tr>
<tr>
<td>Akella, Lalith PP01.01</td>
</tr>
<tr>
<td>Al Omari, Omar PP01.45</td>
</tr>
<tr>
<td>Albarmawi, Husam PP01.36</td>
</tr>
<tr>
<td>Albert, Katherine PP01.10</td>
</tr>
<tr>
<td>Altan, Mehmet PP01.18</td>
</tr>
<tr>
<td>Althouse, Sandra PP01.64</td>
</tr>
<tr>
<td>Alvord, Trevor PP01.76</td>
</tr>
<tr>
<td>Antonoff, Mara PP01.06, PP01.18</td>
</tr>
<tr>
<td>Aptekar, Jacob PP01.78</td>
</tr>
<tr>
<td>Ardito-Abraham, Christine PP01.17</td>
</tr>
<tr>
<td>Areo, Jacqueline OA01.01</td>
</tr>
<tr>
<td>Arnaoutakis, Konstantinos PP01.63</td>
</tr>
<tr>
<td>Arnold Eglolf, Shanna A. PP01.63</td>
</tr>
<tr>
<td>Arriola, Edurne PP01.17</td>
</tr>
<tr>
<td>Attwood, Kristopher PP01.71</td>
</tr>
<tr>
<td>Auger, Claire PP01.33</td>
</tr>
<tr>
<td>Aversano, Jennifer PP01.33</td>
</tr>
<tr>
<td>Awan, Mark M. PP01.76</td>
</tr>
<tr>
<td>Axelrod, Margaret L. PP01.56</td>
</tr>
<tr>
<td>Axelsen, Aitor PP01.17</td>
</tr>
<tr>
<td>Baas, Paul PP01.04</td>
</tr>
<tr>
<td>Backhus, Leah OA01.01</td>
</tr>
<tr>
<td>Baden, Sara OA01.01</td>
</tr>
<tr>
<td>Baden, Tara OA01.12</td>
</tr>
<tr>
<td>Balbach, Meridith L PP01.56</td>
</tr>
<tr>
<td>Bale, Matthew OA01.01</td>
</tr>
<tr>
<td>Balbich, J. OA01.01</td>
</tr>
<tr>
<td>Barth, Benjamin OA01.12</td>
</tr>
<tr>
<td>Bartnitzky, Daniel OA01.01</td>
</tr>
<tr>
<td>Barto, Colin OA01.01</td>
</tr>
<tr>
<td>Batalin, Vitaly OA01.01</td>
</tr>
<tr>
<td>Bauböck, Raimund OA01.01</td>
</tr>
<tr>
<td>Bauböck, Ralph OA01.01</td>
</tr>
<tr>
<td>Bauböck, Wolfgang OA01.01</td>
</tr>
<tr>
<td>Bautista, N. OA01.01</td>
</tr>
<tr>
<td>Bax, Yolanda OA01.01</td>
</tr>
<tr>
<td>Beale, Jonathan OA01.01</td>
</tr>
<tr>
<td>Beashen, Christopher OA01.01</td>
</tr>
<tr>
<td>Bechara, F. OA01.01</td>
</tr>
<tr>
<td>Becquet, Christophe OA01.01</td>
</tr>
<tr>
<td>Bechel, Christian OA01.01</td>
</tr>
<tr>
<td>Behr, Jan OA01.01</td>
</tr>
<tr>
<td>Behr, Marc OA01.01</td>
</tr>
<tr>
<td>Behl, Deepti PP01.01</td>
</tr>
<tr>
<td>Bijelic, Neven OA01.01</td>
</tr>
<tr>
<td>Bihl, Christian OA01.01</td>
</tr>
<tr>
<td>Biozzi, Giuseppe OA01.01</td>
</tr>
<tr>
<td>Bohlen, Anne OA01.01</td>
</tr>
<tr>
<td>Boldt, Christian OA01.01</td>
</tr>
<tr>
<td>Bolli, M. OA01.01</td>
</tr>
<tr>
<td>Bollino, Fabio OA01.01</td>
</tr>
<tr>
<td>Boni, Arnaud OA01.01</td>
</tr>
<tr>
<td>Boni, Piero OA01.01</td>
</tr>
<tr>
<td>Bonini, Stefano OA01.01</td>
</tr>
<tr>
<td>Bonome, T. OA01.01</td>
</tr>
<tr>
<td>Bonnet, N. OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
<tr>
<td>Bonnet, Pierre OA01.01</td>
</tr>
</tbody>
</table>
ABSTRACT AUTHOR INDEX

Esker, Stephen PP01.47
Eccles, Laura PPD04.02
Eagle, Craig PP01.20
de la Mora Jimenez, Emmanuel OA01.0
Dwivedi, Era PP01.58
Dvorkin, Mikhail OA01.05
Du, Robyn PP01.43
Dolezal, James PP01.01
Dimou, Anastasios PP01.55
Dhanasopon, Andrew PP01.12
Desai, Aakash PPD04.01
Derrien Ansquer, Valerie PP01.63
Danese, Mark PP01.70
Deng, Lei PP01.71, PPD04.03
Gosangi, Babina PP01.48
Dawodu, Gbalekan PPD04.01
De Castro, Javier PP01.17
De Jesus Hernandez, Dulce Angelica Ferreira, Carlos Gil
Deboever, Nathaniel PP01.06
Dawar, Richa PP01.74
Davies, Sherri R. PP01.28
Dao, Thang PP01.59
Gamit, Prafullkumar G PP01.23,
Gadgeel, Shirish PP01.10
Geller, Robert PP01.51, PP01.52
Ganzinelli, Monica PP01.01
Ganti, Apar Kishor PP01.76
Gan, Min OA01.05
Gao, Shi OA01.05
Feldon, Jerome PP01.14
Feinberg, Bruce PP01.27
Friedmann, Patricia PP01.04
Fiji, Gayle OA01.05
Forteza, Cameron OA01.12
Franke, Patrick OA01.55
Frohn, Anna OA01.05
Franklin, Patricia OA01.02
Frohn, Clas OA01.05
Franklin, Patrick OA01.01
Franklin, Patricia OA01.05
Franklin, Patrick OA01.01
Garcia-Cillo, Guadalupe Gast, Kelly
Geller, Robert PP01.51
Gentile, Danielle PPD02.01
Gettman, Scott N PPD02.02
Giammaria, Maristella Gabbis, Kim
Gino, Marco OA01.05
Giro, Andrea OA01.05
Gill, Brent OA01.05
Gill, Gopinath OA01.05
Gilleo, Seth OA01.05
Gillieson, Mark OA01.05
Gillieson, Mark OA01.05
Gillieson, Mark OA01.05
Gillieson, Mark OA01.05
Gillieson, Mark OA01.05
Gillieson, Mark OA01.05
North American Conference on Lung Cancer

NACLC 2022 | Conference Program Book

IASLC 2022 | September 23 – 25, 2022 | Chicago, Illinois, USA
Exhibit & Industry Supporter Information

Exhibit Hours
- Saturday, September 24: 09:30 – 18:00
- Sunday, September 25: 09:30 – 12:30

Exhibition Events & Highlights

NETWORKING BREAKS
On Saturday, September 24 and Sunday, September 25, refreshments are available for registered delegates in the Chicago Ballroom FGH on the 5th Floor during the morning and afternoon Networking Breaks.

<table>
<thead>
<tr>
<th>Saturday, September 24</th>
<th>09:30 – 10:00</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>14:30 – 15:00</td>
</tr>
<tr>
<td>Sunday, September 25</td>
<td>09:15 – 09:45</td>
</tr>
</tbody>
</table>

POSTER SESSIONS
The Poster Sessions are an important educational part of this Conference. All poster presentations are located in the Exhibit and Poster Hall. All poster presentations have been assigned a consecutive publication number for locating the abstract / poster in this Program Book and the Abstract Book which corresponds to the Poster Board Numbers.

For further details regarding Poster display and author stand by times, please refer to page 21 in this Program Book.
<table>
<thead>
<tr>
<th>Exhibit Descriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Booth 3</strong></td>
</tr>
<tr>
<td><strong>Booth 4</strong></td>
</tr>
<tr>
<td><strong>Booth 5</strong></td>
</tr>
<tr>
<td><strong>Booth 6</strong></td>
</tr>
<tr>
<td><strong>Booth 7 &amp; 18</strong></td>
</tr>
<tr>
<td><strong>Booth 11</strong></td>
</tr>
<tr>
<td><strong>Booth 14</strong></td>
</tr>
<tr>
<td><strong>Booth 15</strong></td>
</tr>
<tr>
<td><strong>Booth 16</strong></td>
</tr>
<tr>
<td><strong>Booth 17</strong></td>
</tr>
<tr>
<td><strong>Booth 9</strong></td>
</tr>
<tr>
<td><strong>Booth 1</strong></td>
</tr>
<tr>
<td><strong>Booth 2</strong></td>
</tr>
<tr>
<td><strong>Booth 10</strong></td>
</tr>
</tbody>
</table>
Exhibitor Descriptions

Booth 13

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Booth 6

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

Booth 2

Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.

Booth 12

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to patients. Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide.

For more information, visit www.takedaoncology.com.
Industry Sponsored Symposia & Satellite CME Symposia
Saturday, September 24, 2022

IS01 - Satellite CME Symposium by PeerView: Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions
Chicago Ballroom E | 5th Floor
06:45 - 07:45
Taofeek Owonikoko, United States, Carl M. Gay, United States & Jacob Sands, United States

IS02 - Industry Sponsored Symposium by Regeneron: An FDA Approved Treatment Option in Advanced NSCLC
Chicago Ballroom ABCD | 5th Floor
12:00 - 13:00
Eric Nadler, United States

IS03 - Industry Sponsored Symposium by Merck: Personalizing Your Approach With First-Line Treatment Options for mNSCLC
Chicago Ballroom E | 5th Floor
12:00 - 13:00
Marsha Jones, United States & Kelly Pendergrass, United States

IS04 - Satellite CME Symposium by PeerView: Are You Prepared for the New Wave of ADCs in NSCLC7 Innovative Approaches and Practical Considerations in Targeting HER2, HER3, TROP2, and Other Alterations in Advanced Lung Cancer
Chicago Ballroom ABCD | 5th Floor
19:30 - 20:30
Marina Chiara Garassino, United States, Hossein Borghaei, United States & Stephen V. Liu, United States

IS05 - Satellite CME Symposium by PeerView: Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations
Chicago Ballroom E | 5th Floor
06:45 - 07:45
Natalia Lodig, Canada, Zofia Piotrowska, United States & Catherine Shu, United States

Chicago Ballroom E | 5th Floor
12:30 - 13:30
David Waterhouse, United States

Sunday, September 25, 2022

IS05 - Satellite CME Symposium by PeerView: Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations
Chicago Ballroom E | 5th Floor
06:45 - 07:45
Natalia Lodig, Canada, Zofia Piotrowska, United States & Catherine Shu, United States

Chicago Ballroom E | 5th Floor
12:30 - 13:30
David Waterhouse, United States
Editor-in-Chief:
Alex A. Adjei, MD, PhD, FACP
Chairman, Taussig Cancer Institute – Cleveland Clinic, Cleveland, OH USA

*JTO Clinical and Research Reports* is the official open access journal of the International Association for the Study of Lung Cancer. It complements the *Journal of Thoracic Oncology* by offering authors a gold open access publication option and publishing the following article types in particular:

- Phase I trials
- Well performed single-arm phase II trials
- Subset analyses of published trials
- Impactful retrospective studies
- Database and registry analysis
- Large institutional series
- High-quality case reports
- Region-specific clinical trials
- Subspecialty specific thoracic oncology studies
- Selected high-quality meeting reports

Now indexed in PubMed Central

---

Lung Cancer Considered

The official podcast of the IASLC.

Tune in each month for conversations with the researchers, healthcare professionals, patients and advocates from around the world who are making a difference in the treatment of thoracic cancers.

Find new podcast episodes at IASLC.org/Lung-Cancer-Considered

Simply scan the QR Code below and start listening today.

Lung Cancer Considered is funded in part by:
AstraZeneca,
Bristol Myers Squibb,
Lilly Oncology, and
Merck KGaA.

Learn more at JTOCRR.org
IASLC 2022-23

MEETINGS SCHEDULE

IASLC 2022 Asia Conference on Lung Cancer
October 27-29, 2022
Nara, Japan
#ACL22

IASLC 2023 Latin America Conference on Lung Cancer
January 25-27, 2023
Montevideo, Uruguay
#LALCA23

IASLC 2023 Targeted Therapies of Lung Cancer Meeting
February 22-25, 2023
Santa Monica, California
#TTL23

IASLC 2023 World Conference on Lung Cancer
September 9-12, 2023
Singapore
#WCLC23

Scan the QR code for information on upcoming meetings and webinars.

* Location and dates subject to change